Michael Atkins, MD

Articles

Dr Atkins on the Rationale of Investigating Nivolumab/Ipilimumab in RCC

April 6th 2023

Michael B. Atkins, MD, discusses the rationale for launching the phase 2 HCRN GU16-260 trial in patients with advanced renal cell carcinoma.

Dr. Atkins on TFS Outcomes from the HCRN GU16-260 Trial in RCC

February 22nd 2023

Michael B. Atkins, MD, discusses the treatment-free survival outcomes from cohort A of the phase 2 HCRN GU16-260 trial in patients with advanced renal cell carcinoma.

Closing Remarks on the Treatment of Patients With Metastatic Melanoma

May 17th 2022

Experts share closing remarks and provide advice for clinicians treating patients with metastatic melanoma.

Second-line Treatment Strategies for BRAF-mutant Metastatic Melanoma: Additional Patient Scenarios

May 17th 2022

Dr Michael Atkins and Dr Evan Lipson discuss additional second- and third-line treatment options.

Second-line Treatment Strategies for BRAF-mutant Metastatic Melanoma: Patient Profile Revisited

May 17th 2022

Dr Michael Atkins and Dr Evan Lipson revisit the first patient profile to discuss second- and third-line treatment options for patients with metastatic melanoma.

Frontline Trials for BRAF-Mutant Metastatic Melanoma: Relatlimab Plus Nivolumab

May 11th 2022

Data from the RELATIVITY-047 trial, which evaluated relatlimab plus nivolumab in untreated, advanced melanoma were reviewed and clinical implications of these data were discussed.

First-line Treatment Strategies for BRAF-Mutant Metastatic Melanoma: Unmet Needs

May 11th 2022

Dr Michael Atkins and Dr Evan Lipson highlight some of the current unmet needs in the treatment of patients with metastatic melanoma.

First-line Treatment Strategies for BRAF-Mutant Metastatic Melanoma: BRAF/MEK Inhibitors

May 5th 2022

Experts discuss the use of BRAF and MEK inhibitors as first-line treatments for patients with metastatic melanoma.

First-line Treatment Strategies for BRAF-Mutant Metastatic Melanoma: Ipilimumab & Nivolumab

May 5th 2022

Dr Michael Atkins and Dr Evan Lipson review data from the DREAMseq trial, which evaluated nivolumab plus ipilimumab, in treatment-naïve patients with BRAFV600-mutated melanoma.

First-line and Subsequent Treatment Strategies for Unresectable/Metastatic Melanoma: A Patient Profile

April 26th 2022

Dr Michael Atkins and Dr Evan Lipson introduce and discuss a patient with unresectable stage IV metastatic melanoma.

The Current State of Metastatic Melanoma

April 26th 2022

Dr Evan Lipson provides a brief overview of metastatic melanoma including information on incidence and prognosis. He also covers the current state of biomarker testing for patients recently diagnosed with metastatic melanoma.